rilvegostomig + chemotherapy

Rilvegostomig + chemotherapy is a combination therapy under investigation for the treatment of several advanced cancers, primarily biliary tract cancer, HER2-positive gastric cancer, and non-small cell lung cancer (NSCLC). Rilvegostomig is a bispecific monoclonal antibody that targets both programmed cell death protein 1 (PD-1) and T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT), designed to enhance the antitumor immune response by blocking two major inhibitory checkpoints. The chemotherapy components vary by indication and may include gemcitabine and cisplatin (for biliary tract cancer), fluoropyrimidine derivatives plus trastuzumab deruxtecan (for HER2-positive gastric cancer), or platinum-based regimens (for NSCLC). Clinical trials demonstrate promising efficacy, with manageable toxicity, and large phase 3 studies are ongoing in multiple solid tumors. The combination capitalizes on simultaneous immune checkpoint inhibition (through rilvegostomig) and cytotoxic effects (from chemotherapy) for enhanced antitumor activity[1][2][3][4][6].

Brand names

rilvegostomig

Other names

rilvegostomig plus chemotherapy